Background: Zolbetuximab, a monoclonal antibody targeting claudin-18.2 (CLDN18.2), which was recently approved as first-line treatment for advanced gastric cancer (AGC), presents unique safety challenges, particularly infusion-related gastrointestinal toxicity and hypoalbuminemia. This study aimed to present our experience with zolbetuximab administration in patients with AGC, focusing on the safety and management effectiveness of our adapted protocol in routine clinical practice. Methods: This study presents our single-institution real-world experience implementing a proactive management protocol (“Project VYLOY”) using zolbetuximab to mitigate these toxicities. We adopted a standardized stepwise infusion protocol and antiemetic premedication to reduce infusion-related nausea and vomiting. Patients with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma who received zolbetuximab combined with chemotherapy were included. Results: Twenty-four patients were included. The median infusion duration was 215 min, with an interruption rate of 25.0%. In cycle 1, 62.5% experienced infusion-associated adverse events, primarily grade 1 nausea (54%) and vomiting (25%). Hypoalbuminemia (grade ≥ 2) occurred in 57% of first-line patients, potentially linked to zolbetuximab-induced gastritis and gastrointestinal protein loss. Proactive antiemetic support and infusion rate adjustments substantially reduced infusion interruptions in subsequent cycles (10.9%). Patients without prior gastrectomy had higher nausea and vomiting rates, confirming the stomach’s role in mediating toxicity. Conclusions: Our results suggest that proactive management can improve the safety and tolerability of zolbetuximab, especially by reducing infusion-related toxicity in real-world practice.
Anti-programmed death 1 (PD-1) antibodies, a type of immune checkpoint inhibitor (ICI), have enhanced survival rates in non-small cell lung cancer (NSCLC).
Background. In Japan, much preventive medicine outside mandated national programmes is left to municipal discretion, yet the nationwide alignment between these locally administered programmes and graded evidence remains unexamined. We mapped implementation of non-mandatory preventive medicine programmes across Japanese municipalities and quantified evidence–practice gaps. Methods. A nationwide cross-sectional survey was administered to all 1,741 Japanese municipalities between March and August 2025. Implementation (excluding the five mandated cancer screenings under the Health Promotion Act) was defined as municipal provision or subsidisation and calculated on municipality-count and population-weighted bases. Each programme was benchmarked against USPSTF recommendation grades, and an Evidence–Practice Alignment (EPA) score was derived for each municipality (weights: A = + 2, B = + 1, D = − 2, I or ungraded = − 1). Non-response bias was assessed by comparing responding and non-responding municipalities using standardised mean differences derived from national statistical databases. Results. Valid responses were received from 467 municipalities (response rate, 26.8%) across all 47 prefectures. Implementation rates ranged from 0.2% to 92.1% (municipality-count) and 0.0% to 94.4% (population-weighted). Ten Grade A/B programmes had implementation below 50%, including folic acid supplementation (3.2%), syphilis screening (9.6%), and abdominal aortic aneurysm screening (16.1%). Conversely, hepatitis B/C (92.1%, 91.4%) and osteoporosis screening (68.5%) were widely implemented. Several Grade D or ungraded programmes showed appreciable uptake, notably young adult health check-ups (86.3%; ungraded), brain/carotid screening (41.1%; Grade D), and frailty screening (26.1%; ungraded). Population-weighted coverage exceeded municipality-count rates for HIV (48.1% vs 10.1%) and syphilis (48.3% vs 9.6%) screening, indicating concentration in larger municipalities. Prefectural EPA scores ranged from − 4 to 1, with heterogeneity and no clear geographic gradient. Conclusions. Substantial evidence–practice gaps and equity concerns coexist in Japan’s municipal preventive medicine programmes. Our findings support strengthened dissemination of graded evidence to municipal decision-makers and critical reassessment of low-value screening.